EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer

Jeyalakshmi Kandhavelu, Kumar Subramanian, Vivash Naidoo, Giulia Sebastianelli, Phuong Doan, Saravanan Konda Mani iD, Hande Yapislar, Ebru Haciosmanoglu, Leman Arslan, Samed Ozer, Ramesh Thiyagarajan, Nuno R Candeias and 3 more

British Journal of Pharmacology · 2024-01 · 181 (1) · 107-124

DOI: 10.1111/bph.16141 ↗

At a glance

Journal article in British Journal of Pharmacology, 2024-01. Written by Jeyalakshmi Kandhavelu and 14 co-authors. Institution: Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Major MEDLINE topics: Colonic Neoplasms, Antineoplastic Agents, Colorectal Neoplasms. Cited 28 times so far (Crossref); 67 references. The full text is freely available (open access, CC BY 4.0). Funded by: Fundação para a Ciência e a Tecnologia, PT National Funds, South African Medical Research Council.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background and Purpose Colorectal cancer (CRC) is the second most lethal disease, with high mortality due to its heterogeneity and chemo‐resistance. Here, we have focused on the epidermal growth factor receptor (EGFR) as an effective therapeutic target in CRC and studied the effects of polyphenols known to modulate several key signalling mechanisms including EGFR signalling, associated with anti‐proliferative and anti‐metastatic properties. Experimental Approach Using ligand‐ and structure‐based cheminformatics, we developed three potent, selective alkylaminophenols, 2‐[(3,4‐dihydroquinolin‐1(2 H )‐yl)( p ‐tolyl)methyl]phenol (THTMP), 2‐[(1,2,3,4‐tetrahydroquinolin‐1‐yl)(4‐methoxyphenyl)methyl]phenol (THMPP) and N ‐[2‐hydroxy‐5‐nitrophenyl(4′‐methylphenyl)methyl]indoline (HNPMI). These alkylaminophenols were assessed for EGFR interaction, EGFR‐pathway modulation, cytotoxic and apoptosis induction, caspase activation and transcriptional and translational regulation. The lead compound HNPMI was evaluated in mice bearing xenografts of CRC cells. Key Results Of the three alkylaminophenols tested, HNPMI exhibited the lowest IC 50 in CRC cells and potential cytotoxic effects on other tumour cells. Modulation of EGFR pathway down‐regulated protein levels of osteopontin, survivin and cathepsin S, leading to apoptosis. Cell cycle analysis revealed that HNPMI induced G0/G1 phase arrest in CRC cells. HNPMI altered the mRNA for and protein levels of several apoptosis‐related proteins including caspase 3, BCL‐2 and p53. HNPMI down‐regulated the proteins crucial to oncogenesis in CRC cells. Assays in mice bearing CRC xenografts showed that HNPMI reduced the relative tumour volume. Conclusions and Implications HNPMI is a promising EGFR inhibitor for clinical translation. HNPMI regulated apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in CRC cell lines, showing potential as a therapeutic agent in the treatment of CRC.

Subjects

MeSH terms (MEDLINE)

Colonic NeoplasmsAntineoplastic AgentsColorectal NeoplasmsHumansAnimalsMicebcl-2-Associated X ProteinTumor Suppressor Protein p53Proto-Oncogene Proteins c-bcl-2ApoptosisApoptosis Regulatory ProteinsErbB ReceptorsCarcinogenesisCell Transformation, NeoplasticPhenolsCell Line, TumorCell Proliferation

Author keywords

EGFR inhibitoralkylaminophenolsapoptosiscolon canceroncogenesis

Substances

bcl-2-Associated X ProteinTumor Suppressor Protein p53Proto-Oncogene Proteins c-bcl-2Antineoplastic AgentsApoptosis Regulatory ProteinsErbB ReceptorsPhenolsEGFR protein, human

Authors and institutions

  • Division of Oncology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
  • Molecular Signalling Lab, Faculty of Medicine and Health Technology, BioMediTech, Tampere University and Tays Cancer Centre, Tampere, Finland.
  • BioMediTech Institute and Faculty of Medicine and Health Technology, Tampere University, Tampere, Finland.
  • Science Center, Tampere University Hospital, Tampere, Finland.
  • Research and Publication Wing, Bharath Institute of Higher Education and Research, Chennai, Tamil Nadu, India.
  • Department of Physiology, Acibadem University School of Medicine, Atasehir, Istanbul, Turkey.

ORCID profiles: Saravanan Konda Mani, Meenakshisundaram Kandhavelu

Funding

  • Fundação para a Ciência e a Tecnologia
  • PT National Funds
  • South African Medical Research Council

Cite

APA

Kandhavelu, J., Subramanian, K., Naidoo, V., Sebastianelli, G., Doan, P., Konda Mani, S., Yapislar, H., Haciosmanoglu, E., Arslan, L., Ozer, S., Thiyagarajan, R., Candeias, N. R., Penny, C., Kandhavelu, M., & Murugesan, A. (2024). A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. https://doi.org/10.1111/bph.16141

Vancouver

Kandhavelu J, Subramanian K, Naidoo V, Sebastianelli G, Doan P, Konda Mani S, et al. A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer. British Journal of Pharmacology. 2024. doi:10.1111/bph.16141

BibTeX
@article{Kandhavelu2024,
  author = {Kandhavelu, Jeyalakshmi and Subramanian, Kumar and Naidoo, Vivash and Sebastianelli, Giulia and Doan, Phuong and Konda Mani, Saravanan and Yapislar, Hande and Haciosmanoglu, Ebru and Arslan, Leman and Ozer, Samed and Thiyagarajan, Ramesh and Candeias, Nuno R and Penny, Clement and Kandhavelu, Meenakshisundaram and Murugesan, Akshaya},
  title = {A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL‐2/BAX and p53 in colon cancer},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16141}
}
Start for free →